MOUNTAIN VIEW, CA--(Marketwire - May 12, 2009) - REGiMMUNE Corporation today announced that a company abstract has been accepted for presentation at the 2009 American Transplant Congress (ATC, May 30 to June 3, 2009 in Boston, Massachusetts). The poster presentation is titled “Donor-Specific Tolerance Induction by a Liposomal Formulation of KRN7000 (RGI-2001) Alone and in Combination with Low-Dose Sirolimus.” KRN7000 is a synthetic derivative of alpha-galactosylceramide, a small molecule that potently activates natural killer T (NKT) cells. RGI-2001, a proprietary liposomal formulation of KRN7000, is in late preclinical development and REGiMMUNE plans to file an Investigational New Drug (IND) for the prevention of acute Graft-versus-Host disease (GvHD) associated with bone marrow transplantation later this year.
The poster presentation is scheduled during the session “Tolerance I: Regulatory Cells” on Monday, June 1, 2009, in Exhibit Hall C, Hynes Convention Center. It is available for viewing from 8:00 am to 6:30 pm; and the authors, Drs. Omar Duramad and Reiko Namikawa, will be present from 5:30 pm to 6:30 pm for discussion and questions.
The abstract, publication number 1587, is now available on the ACT web site at www.abstracts2view.com/atc/sessionindex.php.
About REGiMMUNE
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The company’s proprietary platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. Treg cells are believed to play a central role in inducing and maintaining immune tolerance. Using its reVax technology, REGiMMUNE is developing the first drugs that are Treg-cell inducing agents.
The company is also applying its reVax technology to develop a range of pipeline products, including its RGI-1000 series for allergy and its RGI-3000 series for autoimmune diseases. Additionally REGiMMUNE is developing its RGI-4000 series for vaccine adjuvants. The company is headquartered in Tokyo, Japan and has a U.S. subsidiary in Mountain View, California. For more information, visit www.regimmune.com.
About the American Transplant Congress
The American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST) for nine years have jointly sponsored an annual meeting, the American Transplant Congress (ATC). The 2009 ATC, being held at the John B. Hynes Convention Center in Boston, is the premier educational event in the field of basic and clinical transplantation. The meeting attracts physicians, surgeons, scientists, nurses, organ procurement personnel, and pharmacists who are interested in the clinical and research aspects of solid organ and tissue transplantation. The program is developed to encourage the exchange of new scientific and clinical information and support an interchange of opinions regarding care and management issues, as well as socioeconomic, ethical, and regulatory issues relevant to organ and tissue transplantation.
US MEDIA CONTACT:
Debra Bannister
530 676-8001
